Timing of ctDNA Testing in Advanced Breast Cancer

Recruiting now

Conditions studied: Advanced Breast Cancer

In brief

This multicenter, prospective observational cohort study aims to investigate the impact of circulating tumor DNA (ctDNA) level and key actionable gene mutation status on prognosis and treatment response in patients with advanced breast cancer.

Key facts

Study ID

NCT07681323

Run by

Geneplus-Beijing Co. Ltd.

People needed

400

Starts

2026-07-08

Expected to finish

2029-06-30

Last updated by the study team

2026-07-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed advanced breast cancer
• Age ≥18 years
• Expected survival >3 months
• Willing to undergo ctDNA testing and sign informed consent form

You may not qualify if…

• The subject has not signed the informed consent form.
• Pregnant or breastfeeding women.
• Other situations deemed by the investigator as unsuitable for inclusion in the study.

Where it is running

• Cancer Institute and Hospital, Chinese Academy of Medical Sciences — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.